Active not recruiting

A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

I5B-MC-JGDQ - ClinicalTrials.gov - NCT03126591

The purpose of this study is to evaluate the safety of olaratumab plus pembrolizumab in participants with previously treated advanced or metastatic soft tissue sarcoma.
How long will I be in the trial?
The duration of your participation depends on how well your disease responds to the study treatment.
Email
Active not recruiting

A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

I5B-MC-JGDQ - ClinicalTrials.gov - NCT03126591

The purpose of this study is to evaluate the safety of olaratumab plus pembrolizumab in participants with previously treated advanced or metastatic soft tissue sarcoma.
How long will I be in the trial?
The duration of your participation depends on how well your disease responds to the study treatment.
Email

Key Requirements

Age :

18+

Sex:

All

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

18+

Sex

All

Participants must

Participant must have a diagnosis of advanced unresectable or metastatic soft tissue sarcoma confirmed by histology

Participant must be able to provide tumor tissue obtained within 6 months of enrolling in the study (if no such tissue is available, must be willing to provide a core or excisional biopsy)

Participant must have an anticipated life expectancy of 3 months or more

Participants must NOT

Participant must not have active autoimmune disease or any other syndrome that require systemic steroids or autoimmune agents in the past 2 years

Participant must not have received a live-virus vaccine within 30 days of planned treatment

Participant must not have inflammatory bowel disease for which immunosuppressive agents were used in the last 2 years

Trial Summary

Conditions the trial is for

Soft Tissue Sarcoma

What the trial is testing?

Olaratumab, Pembrolizumab

Could I receive a Placebo?

no

Enrollment Goal

37

Trial Dates

July 2017 - March 2021

Trial Phase

1

Enter your postal code to find the nearest site

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

18+

Sex

All

Participants must

Participant must have a diagnosis of advanced unresectable or metastatic soft tissue sarcoma confirmed by histology

Participant must be able to provide tumor tissue obtained within 6 months of enrolling in the study (if no such tissue is available, must be willing to provide a core or excisional biopsy)

Participant must have an anticipated life expectancy of 3 months or more

Participants must NOT

Participant must not have active autoimmune disease or any other syndrome that require systemic steroids or autoimmune agents in the past 2 years

Participant must not have received a live-virus vaccine within 30 days of planned treatment

Participant must not have inflammatory bowel disease for which immunosuppressive agents were used in the last 2 years

Trial Summary

Conditions the trial is for

Soft Tissue Sarcoma

What the trial is testing?

Olaratumab, Pembrolizumab

Could I receive a Placebo?

no

Enrollment Goal

37

Trial Dates

July 2017 - March 2021

Trial Phase

1

Not the right fit? Sign up to receive updates on new Soft Tissue Sarcoma trials.

Trial Locations

Hide locations not currently recruiting

Enter your postal code to see sites near you

Soft Tissue Sarcoma Resources

Clinical Trial Participation: What to Expect

Clinical Trial Participation: What to Expect

A clinical trial is a scientific study in people that helps to determine if and how a drug or therapy works. These can also be called clinical studies, or clinical research. Clinical research helps us answer specific questions about an investigational drug , such as: Is it effective? Is it more effective than another established treatment? Is it safe and/or what are its side effects?